NMDA Antagonists for TRD: What the Data Means for You

What the Research Says

A newly published analysis in Psychiatric Times takes a hard look at the side effect profiles and discontinuation rates of NMDA receptor antagonists — the drug class that includes both IV ketamine and FDA-approved intranasal esketamine (Spravato) — in patients with treatment-resistant depression (TRD). The findings carry real weight for anyone currently navigating or considering these therapies.

The clinical guidance emerging from this review is direct: move faster, measure more carefully, and don't let avoidable side effects stall progress. Psychiatrists contributing to the piece are urging a more data-driven approach — optimizing dosing sooner, switching formulations when needed, and using validated tools like the PHQ-9 to track whether patients are actually moving toward remission rather than simply tolerating a protocol.

This isn't a fringe academic debate. As ketamine and esketamine become more widely available through both in-person clinics and telehealth platforms in 2026, understanding what drives patients to stop treatment prematurely — and what can be done about it — is directly relevant to outcomes.

Understanding the Side Effect Landscape

NMDA antagonists are effective, but they come with a side effect profile that's meaningfully different from conventional antidepressants. The most commonly reported effects include dissociation, dizziness, nausea, elevated blood pressure, and perceptual disturbances during or shortly after administration. Most of these are transient — resolving within one to two hours of a session — but their intensity varies significantly by patient, dose, and delivery method.

Discontinuation is a real concern. Across the clinical literature, a subset of patients stop treatment not because the medication isn't working, but because the acute experience feels unmanageable, monitoring feels inadequate, or they simply don't receive enough guidance about what to expect. This is a systems problem as much as a pharmacological one. When providers set clear expectations before the first session, monitor vitals attentively, and offer structured support during the peri-treatment window, dropout rates fall.

IV ketamine and intranasal esketamine differ somewhat in their side effect intensity and onset. IV administration allows for precise dosing and faster clinical adjustment, which is why many experienced providers favor it for more complex or medically sensitive cases. Intranasal esketamine, administered in certified healthcare settings, produces a similar but generally milder dissociative effect. Neither is inherently safer — both require appropriate screening, supervision, and follow-up.

What This Means for Online Ketamine Treatment

For patients exploring telehealth ketamine options, this research adds important context to the provider-vetting process. The clinical community is converging on a consensus: structured monitoring, dose flexibility, and systematic outcome tracking aren't optional extras — they're what separates effective treatment from a missed opportunity.

That has direct implications for how you evaluate any online ketamine provider. Telehealth platforms vary considerably in how rigorously they screen patients before treatment, how they supervise sessions (particularly for at-home protocols), and whether they have a defined process for reassessing your dose or switching approaches if early sessions aren't producing results. The research reviewed in Psychiatric Times makes clear that passive, one-size-fits-all protocols lead to higher dropout and slower remission — exactly the opposite of what patients with treatment-resistant depression need.

Here's what to look for when comparing providers:

• Pre-treatment screening: A responsible telehealth provider should take a complete psychiatric and medical history, screen for contraindications (including cardiovascular risk, active psychosis, and substance use history), and set realistic expectations about the acute experience before your first session.
• Outcome measurement: Look for providers who use validated tools — PHQ-9 is the standard referenced in this research — to track your depression scores across sessions, not just ask how you're feeling informally.
• Dose optimization protocols: The research supports adjusting doses proactively rather than keeping patients on a fixed regimen that isn't working. Ask whether your provider has a clear framework for dose adjustment and when they'd consider switching delivery methods.
• Side effect management: A good provider briefs you on what to expect, has a clinical staff member available during or immediately after sessions, and has a defined follow-up process for the 24-48 hours post-treatment.

On cost: out-of-pocket expenses for telehealth ketamine remain a significant barrier for many patients in 2026. IV ketamine sessions typically range from $400–$800 per infusion; esketamine requires in-office administration and may have partial insurance coverage under certain plans for qualifying diagnoses. At-home oral ketamine protocols offered through telehealth are generally less expensive but come with their own considerations around supervision and clinical oversight. Whichever path you're evaluating, factor in not just the per-session cost but the total treatment course — and be cautious of platforms that make it easy to start but hard to get meaningful clinical support when you need it.

The broader message from the psychiatric community is an encouraging one: these treatments work, and they work faster than many conventional options for TRD. But realizing that benefit depends on staying in treatment long enough to reach remission — which means having a provider who takes the side effect experience seriously and adjusts course when needed. That standard applies whether you're sitting in a clinic chair or logging into a telehealth platform from home.

Source: Psychiatric Times — Side Effect Profiles and Discontinuation Rates of NMDA Receptor Antagonists in Treatment Resistant Depression